Autor(es): Cursiefen S,Mäurer M

Resumo: Intravenous immunoglobulins (IVIg) have been used for treating various neuroimmunological diseases. Over the past decade their efficacy could be demonstrated in placebo-controlled, double-blinded clinical trials. Use of IVIg has become the first-line treatment for Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and rapidly worsening myasthenia gravis. It is also a second-line treatment for dermatomyositis, polymyositis, stiff-person syndrome, and pregnancy- and postpartum-related relapses in multiple sclerosis. Intravenous immunoglobulin is easily available, its administration is uncomplicated, and it has an excellent safety profile. In Germany it has been approved only for GBS; for other indications it has to be used off-label. Here we review the clinical applications and recommendations for the use of IVIg in neurological diseases.

Palavras-Chave: Intravenous immunoglobulin; Mechanism of action; Immune neuropathies; Neuroimmunology; Immunomodulation

Imprenta: Der Nervenarzt, v. 79, supl. 2, p. 67-76, 2008

Identificador do objeto digital: 10.1007/s00115-008-2461-y

Descritores: Guillain-Barre Syndrome - Proteins

Data de publicação: 2008

INDICADORES

ACESSO